Dow Up0.51% Nasdaq Up0.24%

Array BioPharma, Inc. (ARRY)

3.76 Up 0.05(1.35%) 4:00PM EST
|After Hours : 3.76 Up 0.00 (0.01%) 4:45PM EST
ProfileGet Profile for:
Array BioPharma, Inc.
3200 Walnut Street
Boulder, CO 80301
United States - Map
Phone: 303-381-6600
Fax: 303-449-5376

Index Membership:N/A
Full Time Employees:198

Business Summary 

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. Its proprietary clinical programs in Phase II clinical trial include ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease. The company’s proprietary programs also comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; and ARRY-614, a p38/Tie2 dual inhibitor for myelodysplastic syndromes. Its partnered clinical programs include various drug candidates, including Binimetinib, an MEK inhibitor for cancer; Selumetinib, an MEK inhibitor for cancer; ASLAN001/ARRY-543, an HER2/EGFR inhibitor for gastric cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; VTX-2337, a toll-like receptor for cancer; and Danoprevir, a Hepatitis C virus protease inhibitor. The company’s partnered clinical programs also comprise LY2606368, an Chk-1 inhibitor for cancer; GDC-0575, an Chk-1 inhibitor for cancer; ARRY-380/ONT-380, an HER2 inhibitor for breast cancer,; GDC-0994, an ERK inhibitor for cancer; and LOXO-101, an PanTrk inhibitor for cancer. It has collaborations with Celgene Corporation; Celgene Alpine Investment Co., LLC; Genentech, Inc.; Loxo Oncology, Inc; Novartis International Pharmaceutical Ltd.; and Oncothyreon Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Array BioPharma, Inc.

Corporate Governance 
Array BioPharma, Inc.’s ISS Governance QuickScore as of Nov 1, 2014 is 10. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Ron Squarer BSc (Biochemistry), MBA, 47
Chief Exec. Officer and Director
Mr. David L. Snitman Ph.D., 62
Co-Founder, Chief Operating Officer and VP of Bus. Devel.
Mr. R. Michael Carruthers , 56
Chief Financial Officer and Principal Accounting Officer
Mr. Andrew Robbins ,
Sr. VP of Commercial Operations
Dr. Nicholas A. Saccamano Ph.D., 55
Chief Scientific Officer
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders